Skip to main content

Table 1 Demographic and baseline clinical characteristics of patients in the cyclophosphamide (CYC) and mycophenolate mofetil (MMF) groups

From: Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis

Characteristics

CYC (n = 23)

MMF (n = 34)

P value for significance

Age, mean ± SD

46 ± 10.34

45.24 ± 13.87

0.82

Female, n (%)

18 (78.2)

31 (91.18)

0.24

Disease duration in years, mean ± SD

6.04 ± 5.96

4.19 ± 2.82

0.11

Clinical features, n (%)

   

Breathlessness

21 (91.3)

30 (88.2)

0.53

Arthritis

23 (100)

28 (82.4)

0.07

Skin changes

21 (91.3)

30 (88.2)

0.53

Raynaud’s symptoms

17 (74)

18 (52.9)

0.16

Baseline FVC %, mean ± SD

48.74 ± 15.67

53.44 ± 13.69

0.23

Pulmonary artery hypertension, n (%)

2 (2.7)

4 (11.8)

0.63

Anti-scl-70-positive, n (%)

12 (52.17)

16 (47.18)

0.41

  1. FVC forced vital capacity